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Background
Comorbid physical conditions may be more common in people
with autism spectrum disorder (ASD) than other people.
Aims
To identify what is and what is not known about comorbid
physical conditions in people with ASD.
Method
We undertook an umbrella systematic review of systematic
reviews and meta-analyses on comorbid physical conditions in
people with ASD. Five databases were searched. There were
strict inclusion/exclusion criteria. We undertook double review-
ing for eligibility, systematic data extraction and quality assess-
ment. Prospective PROSPERO registration: CRD42015020896.
Results
In total, 24 of 5552 retrieved articles were included, 15 on chil-
dren, 1 on adults, and 8 both on children and adults. Although the
quality of included reviews was good, most reported several
limitations in the studies they included and considerable het-
erogeneity. Comorbid physical conditions are common, and
some are more prevalent than in the general population: sleep
problems, epilepsy, sensory impairments, atopy, autoimmune
disorders and obesity. Asthma is not. However, there are sub-
stantial gaps in the evidence base. Fewer studies have been
undertaken on other conditions and some findings are
inconsistent.
Conclusions
Comorbid physical conditions occur more commonly in people
with ASD, but the evidence base is slim and more research is
needed. Some comorbidities compound care if clinicians are
unaware, for example sensory impairments, given the commu-
nication needs of people with ASD. Others, such as obesity, can
lead to an array of other conditions, disadvantages and early
mortality. It is essential that potentially modifiable physical con-
ditions are identified to ensure people with ASD achieve their
best outcomes. Heightening clinicians’ awareness is important
to aid in assessments and differential diagnoses, and to improve
healthcare.
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Background
In recent years there has been a growing awareness of the
comorbidity experienced by people with autism spectrum disorder
(ASD), particularly regarding psychiatric conditions. (Throughout
this report we used the term ‘comorbid/ity’, which we consider to
be synonymous with the alternative terms of ‘co-occurring’, or
‘coexisting.) An umbrella review of psychiatric conditions in
people with ASD published in 2020 found a very high burden of
comorbidity across several conditions, reported in 26 systematic
reviews and meta-analyses.1 Physical conditions in people with
ASD have received lesser research attention. An article in 2011
reported an urgent need for research in this area because of
limited literature but probably greater comorbidity than in other
people.2
Two reviews in 2013 commented that research into comorbidity
in people with ASD was of recent origin, and much more was
needed.3,4 A scope of the literature in 2018 reported that people
with ASD have high rates of physical comorbidity, but findings
were based on few studies.5 Since then, further studies and system-
atic reviews have been published, although this field of research is
still relatively underdeveloped. Comorbid physical conditions can
significantly affect quality of life, so it is important that practitioners
and carers are aware of commonly occurring conditions to raise
their index of suspicion and address differential diagnosis, thus
resulting in earlier detection and, therefore, treatment, care and
better outcomes.
Aims
The aim of our study was to identify what is and what is not known
about comorbid physical conditions in people with ASD, through
undertaking an umbrella systematic review of systematic reviews
and meta-analyses (as these synthesise existing studies, resulting in
a pooling of knowledge that is more exhaustive than that contained
in single studies).6 Our aims were designed to be of clinical relevance,
not to delineate aetiology. The specific research questions were:
(a) How common are comorbid physical conditions in people with
ASD?
(b) Are specific comorbid physical conditions more prevalent in
people with ASD than in the general population?
(c) Are there gaps in the evidence base on comorbid physical
conditions in people with ASD?
Method
This review was prospectively registered with the International
Prospective Register of Systematic Reviews (PROSPERO, registra-
tion number: CRD42015020896).
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Literature sources
A systematic search strategy was used to identify existing systematic
reviews and meta-analyses relating to comorbid physical conditions
in people with ASD. The search was conducted through five data-
bases: PsycINFO, CINAHL, Medline, Embase and Cochrane data-
bases. The search was performed on the 21 August 2019. No time
limits were applied; all years of literature were searched. The
search was limited to publications in English.
Search terms
A combination of the following search terms was used for
PsycINFO, CINAHL, Medline and Embase databases:
(a) 1. ‘autis*’ AND ‘systematic review’
(b) 2. ‘autis*’ AND ‘meta-analysis’
(c) 3. ‘pervasive developmental disorder’ AND ‘systematic review’
(d) 4. ‘pervasive developmental disorder’ AND ‘meta-analysis’
(e) 5. ‘Asperger*’ AND ‘systematic review’
(f) 6. ‘Asperger*’ AND ‘meta-analysis’
(g) 7. ‘ASD’ AND ‘systematic review’
(h) 8. ‘ASD’ AND ‘meta-analysis’
(i) 9. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8
Inclusion criteria
(a) ASD.
(b) All ages.
(c) Comorbid physical condition(s).
(d) Systematic review or meta-analysis of peer-reviewed research.
(e) For reviews which include people both with and without ASD,
results for people with ASD are presented separately, and/or
>50% of the total sample have ASD.
(f) English language.
Exclusion criteria
(a) Non-human studies.
(b) Brain-imaging studies.
(c) Genetic studies on syndromes.
(d) Studies on symptoms of ASD.
(e) Treatment studies of comorbid physical conditions.
(f) Reviews assessed as low quality using a quality assessment tool.
Procedures
Papers were selected if they met the predefined inclusion criteria.
Papers were initially screened for suitability based on their title and
abstract, and then candidate papers were read in full. A second
reviewer also read a random 10% of titles and abstracts to ensure
the selection approach was systematic. Any discrepancies were
planned to be resolved through discussion. Two authors then read
the full text of the potentially eligible studies to assess their eligibility.
Using a structured database, data were then extracted from the selected
review papers on the number and type of studies included in the
review, size of studies, population types, definition of ASD, study
designs, comparison groups, co-occurring physical conditions
included and their definitions, findings and the quality of the review.
Additional hand searches were performed to check for relevant
reviews or meta-analyses in the references cited in the selected articles.
The Joanna Briggs Institute checklist for systematic reviews and
research synthesis was used to assess quality.6 It includes 11 items
on: explicit statement of the research question, use of inclusion cri-
teria, appropriateness of search strategy, adequacy of the sources
and resources to search, criteria for appraising studies, double
assessment, methods to minimise errors in data extraction, appro-
priateness of methods to combine studies, assessment of publication
bias, whether policy and/or practice recommendations are
supported by the data, and whether directions for new research
are appropriate. We categorised studies as low, medium, or high
quality if they received a score of 0–5, 6–8 and 9–11, respectively.
Reviews that were of low quality on this measure were then
excluded. The authors discussed together the quality assessment
findings to reach agreement.
Results
Figure 1 summarises the number of reviews included/excluded at
each stage. The search returned 5552 records, of which 223
papers were identified to be read in full. There were no disagree-
ments between the first and second reviewer.
The 223 papers were carefully read and classified as either
meeting or not meeting inclusion criteria. This resulted in 27 articles
selected for data extraction. In general, the quality of the reviews was
good. Sixteen studies were assessed as high quality, 8 as medium and
3 were assessed as low quality and excluded from the umbrella
review, resulting in 24 studies being the final number selected for
inclusion in the review.7–30 The most commonly noted omissions
related to quality assessment, publication bias and methods used
to minimise errors in data extraction. The 24 reviews included 12
meta-analyses and 12 systematic reviews without meta-analysis.
The reviews are summarised in Tables 1–4.
Of the 24 included reviews, 6 were on sleep;10–15 3 on sensory
impairments (not sensory sensitivities; 1 on peripheral hearing
loss,18 1 on visual impairment,19 and 1 on visual or hearing impair-
ment20 ); 3 on epilepsy;7–9 3 on oral health;21–23 1 on asthma26 and 1
on allergic asthma;27 1 each on diabetes,16 gastro-intestinal condi-
tions,17 atopic dermatitis,24 autoimmune disease,25 obesity,28 incon-
tinence;29 and 1 review on 5 conditions – immunological, gastro-
intestinal, incontinence, epilepsy and hypospadias.30 Fifteen
studies were on children and young people,11,13,14,16–27 8 were on
children, young people and adults,7–9,12,15,28–30 and 1 study was on
adults only.10
Although the quality of the included reviews was good, most, in
their own quality assessments, reported several limitations in the
papers they included, and also considerable heterogeneity that pre-
cluded meta-analysis for several of the reviews. Studies drew their
samples from a range of settings, including several reliant on clinical
populations, making comparisons difficult. There were also incon-
sistent findings reported between studies in some of the reviews,
hence there is uncertainty in some of the conclusions that can be
drawn. Additionally, as Tables 1–4 show, prevalences with confi-
dence intervals, and odds ratios in comparison with the general
population were often not reported nor possible to synthesise.
Recognising these limitations, our results suggest that answers to
our research questions are as follows.
How common are comorbid physical conditions in
people with ASD?
Comorbid physical conditions are common in people with ASD.
None of the studies enabled us to say how common physical
comorbidities are overall, as the reviews studied specific conditions,
or in one review five types of conditions (i.e. a limited number of
conditions). We did not identify any systematic reviews on overall
comorbidity or multimorbidity in people with ASD.
Are specific comorbid physical conditions more
prevalent in people with ASD than in the general
population?
Some specific comorbid physical conditions are more prevalent in
people with ASD than in the general population.
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(a) Sleep problems are more common in people with ASD than
other people, with some of this attributable to co-occurring
intellectual disabilities.10–15 There are some inconsistencies in
findings, for example regarding any differences in sleep
quality and sleep efficiency.10,14,15 The sleep studies included
objective measures of sleep in people with ASD, and addition-
ally most also considered sleep in relation to some or all of
physical, psychiatric, behavioural, other neurodevelopmental,
and intellectual abilities/conditions, and medication,10–14 or
excluded these.15
(b) Epilepsy is common.7–9,30 The reviews did not report a com-
parison with the general population (with the exception of
one, which included only a single study on epilepsy),30 but
the estimated pooled prevalences are higher than those previ-
ously reported in the general population. Prevalence varies
depending upon co-occurring intellectual disabilities, age and
aetiology of epilepsy.7–9 Epilepsy is more common in females
with ASD than males with ASD.9
(c) Self-inflicted oral soft tissue injury is more common in people
with ASD than the general population.21 Dental caries are
common, but results are inconsistent as to whether they are
more common than in the general population, and on compar-
isons of dental treatment for caries.21–23
(d) Findings on peripheral hearing loss are inconsistent.18 Among
people with hearing impairment, the relative risk of ASD was
high.20
(e) Refractive errors are common but no different to the general
population, whereas strabismus may be higher than for the
general population.19 Among people with visual impairment,
the relative risk of ASD was very high.20
(f) Diarrhoea, constipation, and abdominal pain appear to be
reported more for children with ASD than for their siblings
or general population, although there is some inconsist-
ency.17,30 Hernia was the only gastrointestinal condition
reported to be more common in one of the studies.30
(g) Rates of ASD are higher in people with atopic dermatitis, and
people with atopic dermatitis plus allergic rhinitis, than in
people who do not have these conditions. Autoimmune
disease is also more common than in the general popula-
tion.24,30 Additionally, parents with autoimmune disorders
(hypothyroidism, type 1 diabetes, rheumatoid arthritis, psoria-
sis) are at higher risk of their children having ASD, alluding to
an association between these conditions and ASD.25
(h) Obesity is more common in people with ASD than in the
general population.28
(i) Incontinence is more common in people with ASD than in the
general population.29,30
(j) Hypospadias might be more common in males with ASD, but
the finding relates to only one study.30
Conversely to the conditions above, which appear to be more
common in people with ASD, asthma probably is not,26 and in
PsycINFO
1247
CINAHL
867
Medline
979
Records
identified 
5552
Title and
abstract
reviewed
3554
Full papers
read 
223
Included
24
Did not meet 
inclusion 
criteria 
(n=196); 
Excluded on 
quality criteria 
(n=3)
199
Did not meet
inclusion
criteria
3331
Duplicates
removed 
1998
Embase
2428
Cochrane
31
Fig. 1 Study selection process.
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antipsychotic-exposed youth, incidence of type 2 diabetes was
less common than in those without ASD.16
Are there gaps in the evidence base on comorbid
physical conditions in people with ASD?
There are substantial gaps in the evidence base on comorbid
physical conditions in people with ASD. There is good evi-
dence that sleep problems, epilepsy, sensory impairments,
atopy, autoimmune conditions and obesity are common,
more so than in the general population, despite some incon-
sistencies in findings. However, it is harder to draw conclu-
sions on other conditions, because of fewer studies having
been undertaken, and inconsistency in their findings. The
results point to considerable comorbidity in several areas,
but further research is needed. There were no systematic
reviews that met our criteria in some areas, such as cardiovas-
cular conditions, cancers, neurological conditions apart from
epilepsy, and musculoskeletal conditions.
Discussion
Principal findings and interpretation
Our study has demonstrated that comorbid physical condi-
tions are common in people with ASD. The study is important
as its design enabled coverage of a wide range of physical con-
ditions. There is evidence to suggest that people with ASD
experience health inequalities compared with the general
population, including higher rates of sleep problems, epilepsy,
sensory impairments, atopy, autoimmune disorders and
obesity, and probably also other conditions that have been
studied to a lesser extent. However, evidence is limited regard-
ing other conditions, and has inconsistencies in findings and
methodological differences. There are also few studies on
some conditions. As far as our umbrella review identified,
some areas have not been systematically reviewed at all, such
as cardiovascular conditions, cancers, neurological conditions
apart from epilepsy and musculoskeletal conditions. We there-
fore conclude that comorbidity is common in people with
ASD, but there remain considerable gaps in the evidence
base. Information about the comorbid physical health of
people with ASD is important in order to heighten awareness
for clinicians to aid in their assessments and differential diag-
noses, especially because of the added complexity of such assess-
ments with people with ASD given their communication needs.
While we identified a number of systematic reviews and
meta-analyses on comorbid physical conditions in people
with ASD, and the quality of the reviews was good, they high-
lighted that the quality of many of the individual studies they
included was limited. This included studies of small or highly
selected samples, and with no power considerations. Detailed
information on the samples’ recruitment was often not com-
prehensive or was lacking. In some cases, inconsistent results
were reported as a result of varying study designs, different
source populations and participant characteristics, as well
as small samples. Some studies had unclear statistical
methods or inclusion criteria. Some studies did not discuss
how ASD and its comorbid physical conditions were assessed
and operationalised. Reported prevalence rates varied consid-
erably between studies because of different methodological
designs and limitations.
Our umbrella systematic review does not include single
studies that have not previously been subject to a systematic
review. This does not devalue such studies, but highlights
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Table 2 Systematic reviews and meta-analyses on sleep in ASD
Topic and authors
Method, included studies, quality
assessment Participants, n Population type Comparison groups Findings
Sleep problems in
intellectual
disabilities
(van de Wouw et al
2012)10
Systematic review
3/50 studies reported on ASD
High
n = 259 with ASD
(range 14–168;
median 77)
16–88 years with ASD, all
levels of intellectual
disabilities
Cross-sectional studies
Adults with
intellectual
disabilities without
ASD
1 study reported 44.7% of intellectual disabilities with ASD experienced sleep problems;
2 studies reported no difference in sleep problems or sleep quality between
intellectual disabilities with ASD and intellectual disabilities without ASD; 1 study
reported more sleep difficulties in intellectual disabilities with ASD compared with
intellectual disabilities without ASD
Quality findings:
(a) Prevalence – well-conducted with very low risk of bias
(b) Associated factors – 1 high quality study, 2 with low risk of bias; no information
on ASD diagnosis
Sleep problems
(Elrod and Hood,
2015)11
Meta-analysis
10 studies
High
n = 333 with ASD
(range 8–68;
median 25.5)
Children
Specialty clinics studies
Typically developing
controls
45 min pooled difference in mean total sleep time between ASD with intellectual
disabilities and typically developing, but −7.3 min difference between ASD and
typically developing when intellectual disabilities were excluded. Increase in
difference in mean sleep latency as age increased
Sleep efficiency was poorer with psychotropics and age
Quality findings: small samples
Sleep problems
(Baglioni et al
2016)12
Meta-analysis
3 studies on Asperger syndrome
7 studies on autistic disorder
High
n = 34 with Asperger
syndrome
n = 103 with autistic
disorder
<18 years with Asperger
syndrome in 2 studies;
18–60 years with
Asperger syndrome in 1
study
<18 years with autistic
disorder in 4 studies;
adolescents and adults
with autistic disorder in
2 studies
Typically developing
controls
Diverse sleep alterations found on polysomnography. Sleep continuity disturbance, but
not sleep depth was found in Asperger syndrome and autistic disorder. Reduced
time in rapid eye movement in autistic disorder but not in Asperger syndrome.
Quality findings: small sample sizes, and small number of studies
Intraindividual
variability of
sleep/wake
patterns
(Becker et al
2017)13
Systematic review
3/52 studies reported on ASD
High
n range 186–194 with
ASD
Children
Cross-sectional, and cohort
studies
Typically developing
and other
developmental
disabilities controls
Cross-sectional study: no differences in Intraindividual variability of sleep/wake
patterns. No difference when also subdivided into ± ADHD
Longitudinal: ASD had greater duration and quality of intraindividual variability of sleep/
wake patterns than typically developing children, although within-child variability
was greater than between-child variability
Quality findings: heterogeneity, few studies, not primary findings of studies
Sleep problems
(Diaz-Roman et al
2018)14
Meta-analysis
47 studies; subjective measures in 37
studies, objective measures in 15
studies
High
n range 75–5430 with
ASD for subjective
sleep parameters
n range 144–312 with
ASD for objective
sleep parameters
Children and youth
≤20 years
Case–control studies
Typically developing
controls
ASD differed from typically developing controls in 10/14 subjective sleep parameters
(sleep questionnaire) and in 7/14 objective sleep parameters (polysomnography,
actigraphy, multiple sleep latency test). Including greater bedtime resistance, sleep
anxiety, sleep-disordered breathing, parasomnias, and longer sleep latency and
higher daytime sleepiness. Less consistency about total sleep time. No difference in
subjectively reported sleep quality (although only 3 studies) and sleep efficiency
(only 2 studies)
Quality findings: average quality score of 5.9/9 on the Newcastle–Ottawa Scale;
heterogeneity, publication bias, most not comorbidity free or medication naive
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Table 2 (Continued )
Topic and authors
Method, included studies, quality
assessment Participants, n Population type Comparison groups Findings
Sleep problems
(Carmassi et al
2019)15
Systematic review
103 studies: 12 on circadian sleep
dysrhythmicity (7 in children, 5 in
adults), 74 on sleep disturbances
(65 in children, 9 in adults), 17 on
melatonin alteration
Medium
Circadian rhythmicity
in children n
range 19–198 with
ASD
Sleep disturbance in
children n
range 8–2714 with
ASD
Circadian rhythmicity
in adults n
range 10–41 with
ASD
Sleep disturbance in
adults n range 8–36
with ASD
Melatonin n
range 10–398 with
ASD
All ages
Cohort, cross-sectional or
case–control studies
Typically developing
controls
Sleep disturbances are frequent in ASD, especially short sleep duration, low sleep
quality, low sleep efficiency and circadian sleep desynchronisation such as delayed
phases and/or eveningness. Sleep disturbances and circadian sleep alteration have
been related to severity of ASD symptoms. Melatonin dysregulation, including delay
in melatonin peak and reduction in amplitude may contribute to sleep
desynchronisation in ASD
Quality findings: heterogeneity of studies including diagnostic criteria, measures,
psychiatric comorbidity and psychotropic drugs, small study sizes, not all had
control groups
ASD, autism spectrum disorder.
Table 3 Systematic reviews and meta-analyses on oral health in ASD
Topic and authors
Method, included studies,
quality assessment Participants, n Population type
Comparison
groups Findings
Oral health in
patients with
disabilities
(Bartolomé-Villar
et al 2016)21
Systematic review
10 studies
High
n = 628 with ASD
(range 20–135;
median 55.5)
0–18 years
Records from oral examination in
schools, institutions or clinics;
no information for 6 studies
Typically developing
controls
Inconclusive findings on dental caries: 1 study reported no findings, 2 reported similar
prevalence between ASD and controls, 4 reported lower incidence, and 3 higher
incidence. 1 study reported 38.2% with ASD had gingival inflammation. 2 studies
reported more self-inflicted injury in soft tissues and self-injurious habits in ASD. 1
study reported 60.0% with ASD needed orthodontic treatment compared with
40.0% typically developing; 1 study reported malocclusion disorders in 60.0% of ASD
Quality findings: no information on ASD diagnosis
Oral health
(Da Silver et al
2016)22
Meta-analysis
7 studies: 7 on dental caries,
3 on periodontal disease
High
n range 22–483 with
ASD
2.5–21 years – Pooled prevalence of dental caries 60.6% (95% CI 44.0–75.1%); pooled prevalence of
periodontal disease 69.4% (95% CI 47.6–85.0%)
Quality findings: Newcastle-Ottawa Scale scores were 9–12; 2 were rated high quality
and 5 were rated medium quality, so moderate to low risk of bias
Dental caries
(Robertson et al
2019)23
Meta-analysis
8/25 studies were on ASD; 2
studies included care index
and restorative index
High
n = 737 with ASD
(range 30–135;
mean 92)
3–16 years
Clinical examinations
Typically developing
and healthy
controls
No difference in caries experience; mean DMFT 1.10 v. 1.01 in controls. Opposite
results on care index and restorative index in 2 studies
Quality findings: Newcastle-Ottawa Scale average score across all studies was 5.2
showing a medium to high risk of bias; 1 was high quality, 9 medium quality and 15
were low quality
ASD, autism spectrum disorder; DMFT, decayed, missing and filled teeth index.
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Table 4 Systematic reviews and meta-analyses on diabetes, gastro-intestinal problems, hearing, vision, dermatitis, autoimmune disease, asthma, obesity, incontinence, and other conditions in ASD
Topic and authors
Method, included studies, quality
assessment Participants, n Population type Comparison groups Findings
Diabetes when
exposed to
antipsychotics
(Galling et al
2016)16
Meta-analysis
13 studies
High
n = 185 105 youth
exposed to
antipsychotics
(range 179–
107 551;
median 5370)
Children and youth
Database of medical
records, prospective
cohort and case–control
studies
Psychiatric controls
unexposed to
antipsychotics (7
studies), healthy
controls (8), no
controls (2)
In antipsychotic exposed youths, ASD was associated with lower incidence of type 2
diabetes mellitus than non-ASD (P = 0.48). Greater incidence of type 2 diabetes
mellitus was associated with second-generation antipsychotics (P ≤ 0.05)
Quality findings: no information on ASD diagnosis
Gastrointestinal
problems
(McElhanon et
al 2014)17
Meta-analysis
15 studies
High
n = 2215 with ASD
(range 33–589;
median 75)
0–18 years
Studies of children with
known gastrointestinal
diagnoses were excluded
Community wide (8
studies), diagnostic clinics
(4 studies), other medical
settings (3 studies)
Typically developing
children or siblings
General gastrointestinal concerns: OR = 4.42 (95% CI 1.90–10.28); diarrhoea: OR = 3.63
(95% CI 1.82–7.23); constipation: OR = 3.86 (95% CI 2.23–6.71); abdominal pain:
OR = 2.45 (95% CI 1.19–5.07)
Quality findings: no studies included diagnosis of gastro-intestinal problems, they relied
on chart reviews or questionnaires
Peripheral hearing
loss
(Beers et al
2014)18
Systematic review
5 studies
Medium
n = 349 with ASD
(range 22–199;
median 37)
Children and adolescents
Hearing tests
Typically developing
participants in 1
study
Inconsistent findings: 2 studies reported normal peripheral hearing; 2 reported possible
increased peripheral hearing loss, but no prevalence estimates; 1 reported
prevalence of 3.5% in 199 children and adolescents with ASD
Quality findings: lack of detail on sample to generalise findings
Visual impairment
(Butchart et al
2017)19
Systematic review
7 studies
Medium
n = 1035 with ASD
(range 18–324)
1–22 years
6 case record reviews
from screening studies; 1
screening study of
children with ASD and
visual impairment
Previously published
literature
22.9–32.7% had refractive errors, similar to rates in the general population (29.5% at 6–
7 years and 32.3% at 12–13 years). 8.3% had strabismus, higher than rates in the
general population (1.5–5.3%)
Quality findings: 6 studies were rated as moderate, and 1 as strong on quality. Weak
findings were mostly for confounders and withdrawals. Specific points included
chart reviews, lack of detail on sample selection, small sample sizes, no visual acuity
testing
Visual or hearing
impairment
(Do et al 2017)20
Meta-analysis
15 studies: 8 visual impairment,
5 hearing impairment, 2 both
High
Unknown n with visual
or hearing
impairment
1–18 years
Cross-sectional and case
series, and retrospective
case-note review
Previously published
literature
19% (13–25%) of visually impaired had ASD; relative risk of ASD was 31.0 times. 9% (6–
12%) of hearing impaired had ASD; relative risk of ASD was 14.1 times
Quality findings: selection bias (clinical populations), ASD diagnosis, unclear reporting,
confounding factors, heterogeneity
Atopic dermatitis
(Billeci et al
2015)24
Systematic review
18 studies
High
n = 1 245 225 with
atopic dermatitis
(range 40–
1 000 000;
median 1955.5)
n with ASD not
provided for all
studies
0–2 years
Case–control studies,
national surveys or
population studies
Typically developing
and healthy controls
1 reported 2.2% with atopic dermatitis had ASD, 0.9% without atopic dermatitis had
ASD. 14 studies considered dermatitis with other atopic disorders:
dermatitis in 3.8–64.2% with ASD compared with 0.0–15.8% in typically developing;
dermatitis + allergic rhinitis in 3.0–13.3% with ASD compared with 0.0–2.5% in
typically developing; dermatitis + asthma in 2.5–9.5% with ASD compared with 2.5–
4.0% typically developing
Quality findings: no information on ASD diagnosis
Autoimmune
disease
(Wu et al
2015)25
Meta-analysis
11 studies
High
n range 102–857 014
family members
3 cohort studies, 6 case–
control studies, 2 cross-
sectional studies
Clinical samples, register
data, autism society
Family members Family history associated with higher risk of autism in children:
All autoimmune diseases combined −28% (95% CI 12–48%); hypothyroidism –
OR = 1.64 (95% CI 1.19–1.91); type 1 diabetes – OR = 1.49 (95% CI 1.23–1.81);
rheumatoid arthritis – OR = 1.51 (95% CI 1.19–1.91); psoriasis – OR = 1.59 (95% CI
1.28–1.97)
Quality findings: potential publication bias for all autoimmune conditions combined,
and for type 1 diabetes
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Table 4 (Continued )
Topic and authors
Method, included studies, quality
assessment Participants, n Population type Comparison groups Findings
Asthma
(Zheng et al
2016)26
Meta-analysis
10 studies
High
n = 8809/175 406 with
ASD
Children
Case–control, cohort or
cross-sectional studies
Typically developing
controls
No association between asthma and ASD: pooled OR = 1.26 (95% CI 0.98–1.61) for
prevalence of asthma in ASD. In the case–control studies, pooled OR = 0.98 (95% CI
0.68–1.43)
Quality findings: 9 studies high quality, 1 study moderate quality, average
Newcastle-Ottawa Scale score = 7/9
Allergic asthma
(Tonacci et al
2017)27
Systematic review
18 studies
High
n range 15–14 812
with ASD
Children
8 case–control studies, 8
nationwide-studies, 2
epidemiological studies
Typically developing
controls
A ‘slight correlation’ found between asthma and ASD in 11/18 studies
Quality findings: small sample sizes, many methodological limitations in studies, narrow
age range in some, findings uncertain
Obesity and
overweight
(Zheng et al
2017)28
Meta-analysis
15 studies (10 objectively
measured, 3 parental reports, 2
medical records)
High
n = 1 045 538 with ASD
(range 40–986 352)
Mean age 6.6 years (s.d. = 2.1
years) to
74.38 years (s.d. = 22.3
years)
11 cross-sectional studies;
4 case–control studies
Typically developing
controls
Obesity was higher than controls, OR = 1.84 (95% CI 1.37–2.48); overweight was not
higher than controls, OR = 1.07 (95% CI 0.83–1.38)
Quality findings: findings were robust
Incontinence
(Niemczyk et al
2018)29
Systematic review
19 studies
Medium
n = 7033 with ASD
(range 25–5076
with ASD)
2–18 years in 16 studies,
adults in 1 study, children
and adults combined in 1
study
Typically developing
controls
Nocturnal enuresis rates were 2–90%, median 22.6% in 13 studies. Daily urinary
incontinence rates were 13.3–55% in 4 studies. Faecal incontinence rates were 2–
70.6%, median 12% in 11 studies. Incontinence rates were higher than typically
developing controls in 4/5 studies
Quality findings: no population-based samples, selected samples, retrospective
analyses, missing diagnostic criteria for ASD and for incontinence
Medical conditions
(Muskens et al
2017)30
Systematic review
5 studies on immunological
conditions, 5 studies on
gastrointestinal problems, 1
study on genitourinary
symptoms, 1 study on epilepsy,
1 study on hypospadias
High
n range 26–14 812
with ASD
1–26 years in 11 studies; 0–
65 years in 2 studies
7 cross-sectional studies;
6 case–control studies
Controls including
healthy children,
siblings or family
Allergic disease or autoimmune disease was higher than controls with OR = 1.22 (95%
CI 1.13–1.31) and OR = 1.36 (95% CI 1.01–1.83) respectively, or no different. Children
with atopy had HR = 3.40 for developing autism, there was no difference compared
with controls in rates of herpes simplex. 3 studies report gastrointestinal symptoms
to be higher than controls (1 specifically reports constipation and chronic
diarrhoea). 1 reports no difference, except hernia with OR = 2.6 (95% CI 1.08–6.2). 1
reports no difference. Nocturnal enuresis and urinary incontinence more common
than in controls in 1 study. Epilepsy more common than in controls in 1 study (3.9%
v. 2%). Hypospadias more common than in controls in 1 study with OR = 3.20 (95% CI
2.8–3.8)
Quality findings: only studies assessed to be high quality were selected
ASD, autism spectrum disorder; OR, odds ratio; HR, hazard ratio.
Rydzew
ska
et
al
8Dow
nloaded from
 https://w
w
w
.cam
bridge.org/core. 09 N
ov 2020 at 16:09:25, subject to the Cam
bridge Core term
s of use.
where further research endeavours would be useful. Our umbrella
approach has the advantage of being suitable to answer the research
questions we posed in one report.
Strengths and limitations
The strengths of this review include its broad reach, the prospective
registration of the review protocol, clear inclusion and exclusion cri-
teria, a comprehensive search strategy including searching multiple
databases, and duplicate study selection and data extraction, and
quality assessment. The review is limited by excluding papers not
written in English. Our review was of systematic reviews only;
hence, it does not include any physical conditions that have not
been subject to systematic review.
Implications
People with ASD experience more comorbid physical conditions
than other people (although we draw no conclusions on shared aeti-
ologies as we did not investigate that). Clinicians require heightened
awareness of these high rates of comorbidities in order to improve
assessments and diagnoses so that people with ASD can receive
the best possible healthcare and support they require. Some of
their comorbidities are likely to compound health assessments
and interventions if health professionals are unwary of their exist-
ence, such as sensory impairments, given the communication
needs that people with ASD already experience. Other comorbid-
ities, such as obesity, if not addressed, can lead to an array of
other conditions, disadvantages and early death. Given the impact
that ASD can have on the individual, it is essential that all other,
potentially modifiable health conditions are identified and
managed to ensure that people with ASD achieve their best
outcomes.
Future research
Comorbid physical conditions occur more commonly in people
with ASD compared with the general population, but the evidence
is limited. Given that physical conditions can have substantial
bearing on function, and quality of life, further robust research is
needed. The prevalence of conditions and their associations needs
to be more firmly established, including for physical conditions
that have to date received little attention. This would form a basis
from which a better understanding of the long-term impact on
quality of life could be gained, a start towards improved understand-
ing of causation, and development of interventions to improve
health. Further studies are also warranted on physical conditions
commonly diagnosed in the general population, such as cancers,
cardiovascular disorders and on physical comorbidities in ageing
populations, to investigate how they have an impact on people
with ASD. This in turn will allow for informed decision-making
around healthcare, service commissioning and provision for
people with ASD.
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